Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma
Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab
The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?
Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report
Is Dietary Acrylamide Intake Associated With the Development of Bladder Cancer?
Does a Family History of Any Cancer Increase the Risk for Bladder Cancer?
Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?
Can Treatment-Specific COXEN Scores Predict Responses to Neoadjuvant Chemotherapy for Bladder Cancer?
Diagnostic Utility of Serum N‐glycan Profiles in Urothelial Carcinomas
TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy
Does Use of Aspirin Improve Outcomes in Older Adults With Bladder Cancer?
Prescription of Psychotropic Drugs in Older Patients With Bladder Cancer
Low-Dose BCG Tokyo Strain for Non–Muscle-Invasive Bladder Cancer
Unleashing the Therapeutic Potential of Natural Compounds Against Bladder Cancer
Systemic Treatment of Metastatic Bladder Cancer: Dutch Study of Current Clinical Practice
Radical Cystectomy Versus BCG Treatment for High-Risk Bladder Cancer
Novel Prognostic Biomarker for Bladder Cancer Investigated
Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks
Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?
Measures of Tumor Heterogeneity: Useful Biomarkers of Bladder Carcinoma?
Study Identifies Potential Biomarker of Bladder Carcinoma Recurrence
Impact of Preoperative Positive Voided Urine Cytology on Prognosis in Urothelial Cancer
Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer
Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial
Pelvic Radiotherapy Combined With Chemotherapy in Metastatic Urothelial Cancer
Predicting Risk of Recurrence in Nonmuscle‐Invasive Bladder Cancer
Preoperative Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma
Nab-paclitaxel Versus Paclitaxel in Metastatic Urothelial Cancer
Surveillance Strategy for Patients With Upper Tract Urothelial Carcinoma
Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update
Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma
Targeting Bladder Carcinoma in Situ With Novel Gene Therapy
After Surgery for Upper Urinary Tract Urothelial Carcinoma: Surveillance or Chemotherapy?
Potential Genomic Predictors of Outcomes in High-Grade T1 Bladder Cancer
DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma
Combination Regimen Under Study in Metastatic Urothelial Carcinoma
Update on Managing Non–Muscle-Invasive Bladder Cancer
Can Leukocyte Telomere Length Predict Bladder Cancer Risk?
Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?
Early Results With Buparlisib in Treatment of Metastatic Urothelial Carcinoma
Testicular Tuberculosis: Case Study of Rare Complication of Urothelial Cancer Treatment
Perioperative Chemotherapy for High‐Risk Upper Tract Urothelial Carcinoma
Early Findings With Magnetic Resonance–Guided Radiotherapy for Bladder Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.